Tecan posts 2025 net loss after $140 mln writedown, warns on margins

Tecan booked a CHF 139.5m non-cash impairment, driving a 2025 net loss of CHF 110.7m versus a CHF 67.7m profit a year earlier and EPS of CHF -8.74 vs +5.30. Full-year sales fell 5.5% to CHF 882.5m (down 1.6% in local currencies) and adjusted EBITDA declined to CHF 142.1m (margin 16.1% vs 17.6%), with FX and tariffs a ~200bp drag. Management is restructuring the Partnering Business, discontinuing acquired design functions, launching a “Rewired” transformation, and guiding 2026 sales growth in low single digits with adjusted EBITDA margin of 15.5–16.5% (110bp FX/tariff headwind); the board proposed an unchanged CHF 3 dividend and reiterated medium-term targets of CHF 1bn sales and 20% adjusted EBITDA by 2028.

Analysis

The write-down and decision to remove in-house design capabilities is a structural signal: Tecan is moving from a design-led OEM model toward a manufacturing/service-led model. That will favor contract manufacturers and vertically integrated plants that can scale low-mix, high-yield production, and it increases the bar for any competitor that still carries bespoke design cost structures. Expect customers to test alternative suppliers during the transition window, creating short-term revenue volatility but a pathway to structurally higher gross margins if execution is clean.

Currency and tariff pressure have functionally reset the company’s margin baseline versus peers with more diversified geographic footprints. Until FX and trade-costs stabilize, pricing power will matter far more than product differentiation — companies that can reprice via service models or shift production footprints will protect margin, while fixed-cost OEMs will compress. Hedging behavior and capex redeployment (toward lower-tariff geographies) are immediate levers to watch over the next 3–12 months.

Demand dynamics are bifurcated: academic/public lab funding and China-facing end markets will determine the pace of recovery, so order-entry momentum is the first reliable leading indicator. If order acceleration persists through two consecutive quarters, upside re-rating is plausible within 6–12 months; if China/public funding remains weak, downside could cascade as customers defer new builds. The company’s ability to convert strong cash flow into rapid restructuring and targeted M&A of complementary IP will be the decisive catalyst for hitting medium-term margin targets.

Execution risk is binary: successful Rewired execution can deliver outsized returns as restructuring resets cost structure, but missteps (customer attrition, failed outsourcing integrations) would extend impairment cycles. Dividend continuity and high cash conversion provide a defensive floor, so traded outcomes should be framed around execution milestones (quarterly order trends, announced outsourcing partners, and FX stabilization).

Key Decisions for Investors

• Short TECN (Swiss listing) into near-term weakness — 3–6 month horizon. Size 2–4% portfolio, target a 20–30% downside if order momentum and APAC demand do not improve; stop-loss at 10% adverse move. Rationale: restructuring execution risk and FX/tariff headwinds will compress near-term earnings before potential medium-term recovery.
• Buy TECN 18–36 month LEAP calls (or buy stock with protective puts) as a turnaround play — 12–24 month horizon. Allocate 1–2% portfolio to long options to capture asymmetric upside if Rewired achieves material margin improvement and order conversion; max loss limited to premium. Hedge by selling a nearer-term call or buying a 6–9 month put to protect against execution missteps.
• Long DHR (Danaher) or TMO (Thermo Fisher) — 6–12 month horizon, overweight relative to OEM peers. Size 3–5% portfolio; target 15–25% upside from market share gains while downside is cushioned by diversified product mix and stronger pricing power. Use this as a relative-value hedge against short TECN exposure.